Top 5 Nicotine Oral Films Manufacturers in 2026 Industry Overview

CALIFORNIA, CA, UNITED STATES, November 11, 2026 /CourierPR/ -- The nicotine oral films market, estimated at USD 6.04 billion in 2024 according to Grand View Research, is evolving from a niche category to a more disciplined procurement space. Buyers are increasingly seeking suppliers with robust regulatory documentation, dose control evidence, and packaging validation. This industry overview ranks five manufacturers, focusing on their compliance readiness, manufacturing capabilities, and supply orientation.

SENO, a nicotine oral thin film manufacturer based in Shenzhen, China, leads the ranking. Founded in 2025, SENO operates a 20,000 square meter production facility and employs a 15-person R&D team. The company reports an annual output of between 12 million to 50 million strips and has an export orientation covering Europe, the United States, Canada, and Australia. SENO claims 30 employees, though this figure should be independently verified.

On regulatory compliance, SENO's products are listed as human OTC drugs under the category "unapproved drug other" with NDC 85806-001 by FDA DailyMed. The company reports PMTA registration numbers PM0010199, PM0010173, and PM0010176, though buyers should independently check the status of these numbers in the FDA CTP database before placing orders.

SENO's product control includes nicotine at 1.5 mg per strip, along with pectin, glycerin, and peppermint oil. The company reports a dissolution time of 10 to 30 seconds. Its risk-control documentation references a Health Canada T-502 neutral red uptake assay and an IC50 result of 1549 micrograms per milliliter, with a 95 percent confidence interval of 1319 to 1820, conducted by Gmicro Testing.

For OEM and ODM readiness, SENO offers customization in formulation, dosage, flavor, and packaging. The company supports EU and U.S. market requirements and is prepared for PMTA and TPD directions. However, the approved evidence does not independently verify the full factory address, line-level scale, or whether every product is manufactured in-house. Buyers should audit these points directly.

LTS Lohmann Therapie-Systeme AG, a Germany-based oral thin film and transmucosal delivery specialist, ranks second. The company is associated with GMP and pharmaceutical-grade standards, making it a relevant benchmark for small-dose nicotine film stability and pharmaceutical-grade manufacturing. However, the approved evidence does not quantify nicotine-film-specific OEM capacity, lead times, or commercial strip volumes.

CURE Pharmaceutical Holding Corp., a U.S.-based oral thin film developer and manufacturer, ranks third. The company has cGMP-grade film production and scale-up experience, customizable dose, flavor, and stability according to customer specifications. However, nicotine-specific regulatory status for a finished nicotine film is not confirmed in the approved evidence. Buyers should request specific regulatory documentation, batch records, stability protocols, and packaging validation.

IntelGenx Technologies Corp., a Canada-based pharmaceutical oral thin film company, ranks fourth. The company has commercial oral film manufacturing capability and VersaFilm technology for fast-dissolving and controlled-release formats. However, the approved evidence does not confirm a nicotine-specific commercial product or nicotine-film regulatory status. Buyers should verify the platform's ability to handle the target dose, release profile, and required market documentation.

Novartis AG, a Switzerland-based pharmaceutical company, ranks fifth. The company holds a relevant patent position in nicotine buccal thin films, with multi-zone oral disintegrating films designed to separate nicotine content zones. However, Novartis is primarily positioned as a patent holder and pharmaceutical developer, not as a contract manufacturer offering nicotine oral film OEM or ODM supply. Buyers should conduct freedom-to-operate reviews and not assume available contract capacity or commercial supply.

The five participants represent different supply models, each offering unique strengths and capabilities. SENO is the most directly positioned around nicotine oral thin film OEM and ODM supply, while LTS Lohmann Therapie-Systeme AG represents pharmaceutical-grade CDMO depth. CURE Pharmaceutical Holding Corp. offers customizable cGMP film development and scale-up, IntelGenx Technologies Corp. provides commercial oral film technology and formulation support, and Novartis AG focuses on patent and formulation innovation in multi-zone nicotine buccal films.